The Medicare GLP-1 Bridge is the first route by which a Medicare beneficiary can get a weight-loss GLP-1 at a predictable price. It is also a demonstration with an end date, three covered products, a disqualifying diagnosis list, and four situations in which $50 a month is the worse of the available prices.
Everything on this page comes from CMS's own FAQ pages for beneficiaries, prescribers and pharmacies, and from Medicare.gov, read on 2026-09-19. Why Medicare could not cover these drugs before is a statutory question answered on our page about what decides GLP-1 insurance coverage; what everything else costs is on the GLP-1 cost page. This page is the programme.
The shape of it, in eight lines
| What | A short-term CMS demonstration, not a Part D benefit and not a plan |
|---|---|
| Authority | Section 402(a)(1)(A) of the Social Security Amendments of 1967, applied to Part D by section 1860D-42(b) of the Social Security Act |
| When | 2026-07-01 to 2027-12-31 |
| Where | Nationwide, all states and territories |
| Price | $50 for a monthly supply |
| Drugs | Foundayo; Wegovy injection and tablets; Zepbound KwikPen only |
| Indication | Weight management only |
| Run by | Humana, as central processor, on the LI NET infrastructure |
The structural fact worth holding onto is in the first line. The Bridge operates outside the Part D benefit's coverage and payment flow. Part D sponsors carry no risk for the drugs it furnishes and did not have to opt in for their members to use it. That is what makes it work nationwide from a standing start, and it is also the source of every one of the traps below.
Who qualifies
A prescriber has to attest, on a prior authorisation form, that the beneficiary is prescribed the drug to reduce excess body weight and maintain that reduction alongside ongoing lifestyle modification including structured nutrition and physical activity, and that the person is 18 or over and met one of these three thresholds:
| At the time therapy began | Additional diagnosis required |
|---|---|
| BMI ≥ 35 | none |
| BMI ≥ 30 | heart failure with preserved ejection fraction, or uncontrolled hypertension, or chronic kidney disease stage 3a or above |
| BMI ≥ 27 | prediabetes, or previous myocardial infarction, or previous stroke, or symptomatic peripheral artery disease |
CMS defines uncontrolled hypertension inside the criterion rather than leaving it to judgement: systolic above 140 mm Hg or diastolic above 90 mm Hg, despite concurrent treatment with two antihypertensive medications. Prediabetes is defined by American Diabetes Association guidelines.
Eligible plan types are a standalone prescription drug plan, a Medicare Advantage coordinated care plan with drug coverage (HMO, HMOPOS, local and regional PPO), a Special Needs Plan, an employer or union group waiver plan, and the LI NET programme. Private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organisations, fallback plans and religious fraternal benefit plans are excluded unless the beneficiary also holds a standalone drug plan. Dually eligible beneficiaries in an eligible plan type can use it.
The timing rule, with CMS's own worked example
The criteria are met at initiation of GLP-1 therapy, not at the date of the request — including for someone who started before joining Part D or before the programme existed. CMS publishes the example, and it is the clearest thing on the page:
"if a beneficiary initiated GLP-1 therapy in September 2024 with a body mass index (BMI) of 37 and has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider should attest that the beneficiary met the BMI ≥35 criterion at the time therapy was initiated."
Losing weight, in other words, does not disqualify you from the programme that helped you lose it. That is the right design and it is not the way prior authorisation usually works.
The diagnosis that disqualifies you
Here is the part of the Bridge most likely to catch someone out, and it inverts the usual intuition that a sicker patient gets more help.
Type 2 diabetes, moderate-to-severe obstructive sleep apnoea and noncirrhotic MASH all make a beneficiary ineligible. Not ineligible for a GLP-1 — ineligible for the $50. CMS is explicit that this holds "even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria."
The logic is administrative rather than clinical. Those three indications are already covered by Part D, so a beneficiary who has one should obtain the drug through their plan. The Bridge exists for the gap: people whose only indication is weight, which was the indication the statute excluded.
The consequence is a two-tier price that depends on a diagnosis rather than on a drug. A beneficiary with a BMI of 36 and nothing else pays $50. The same beneficiary with type 2 diabetes pays whatever their plan's cost-sharing comes to, which may be more, and which will at least count toward their out-of-pocket total. Which brings us to the part of the design that a press release cannot hold.
Four ways $50 is the worse price
The Bridge sits outside Part D, and CMS states the three consequences in a single sentence repeated across all three FAQ pages: the Part D deductible does not apply, no part of the $50 counts toward the beneficiary's TrOOP costs, and there is no low-income subsidy provided for LIS beneficiaries.
Unpacked, with a fourth:
- A low-income subsidy is worth nothing here. The Part D low-income subsidy exists to reduce cost-sharing for beneficiaries with limited income, and for a covered drug it can bring a copay down to a few dollars. Inside the Bridge there is no LIS. For the beneficiaries with the least money, $50 may be the highest of the prices on offer rather than the lowest.
- The $50 does not move you toward the out-of-pocket cap. Part D has an annual out-of-pocket limit, and reaching it is what protects a beneficiary with high drug costs for the rest of the year. Twelve Bridge fills come to $600 of spending that counts toward nothing. A plan-covered GLP-1 fill, however much it cost, would have counted.
- No coupon may be applied. CMS states the Bridge is the primary payer, will not coordinate benefits with other payers, and that "coupons and discount programs may not be applied to Medicare GLP-1 Bridge claims, regardless of funding source" — a prohibition written to cover "any discount or assistance program that systematically or routinely reduces or subsidizes the beneficiary's copay." The manufacturer savings offers documented on our cost pages are outside this door, not stackable with it.
- If your plan already covers it, you are ineligible. Someone whose Part D plan covers their GLP-1 cannot use the Bridge at all, and a single Part D fill after a Bridge approval ends Bridge eligibility for good.
None of this makes the programme a bad deal. For a beneficiary paying self-pay prices around $349 a month, $50 is a very large reduction. It makes the programme a deal that has to be checked against the specific plan, because for some beneficiaries the cheaper door is the ordinary one.
The mechanics, for the sake of the record
CMS chose Humana as the single central processor, on the grounds that it already administers the Limited Income Newly Eligible Transition programme and so has the end-to-end capability and national scale. Claims go to a dedicated Bank Identification Number and Processor Control Number, 028918 MEDDGLP1BR, submitted electronically on the NCPDP standard; paper claims and direct member reimbursement are not accepted. Pharmacies do not opt in and are charged no transaction or click fees.
What the pharmacy is paid: the drug's wholesale acquisition cost, less the $50 copay, plus a $3 dispensing fee — $5 for a beneficiary in long-term care — settled within 14 days of adjudication. CMS clarified the wholesale-acquisition-cost basis in an update dated 2026-03-09.
That last detail is the most consequential number in the design, and it is in a pharmacy FAQ rather than in the announcement. Wholesale acquisition cost is the manufacturer's published price to wholesalers before any rebate. Our cost page records a published list price of $1,349.02 a month for Wegovy and $1,088 for Zepbound, against a self-pay price of $349 for most Wegovy pen doses read from NovoCare on 2026-09-19. So a cash customer with no insurance at all buys at roughly a quarter of the price the Bridge pays, and the difference is public money. Whether that is simply the cost of standing a nationwide programme up in months without asking any plan to bear risk is a policy question; the arithmetic is not in dispute.
The fill rules are tight. One monthly supply of 28 or 30 days per fill. No 60-day or 90-day fills. No partial fills. A point-of-sale override exists for vacation fills, via submission clarification code 003; there are no manual overrides and no overrides for lost or stolen medication. Pen needles for the Zepbound KwikPen are not covered by the Bridge and should not be billed to it or to the Part D plan.
Prior authorisation is valid through 2027-12-31 and carries over refills and dose changes. A decision arrives within 72 hours. Switching to a different covered drug needs a new authorisation. A Part D fill, or a move to an ineligible plan type, ends eligibility and produces a rejection at the counter.
Three products, and the Zepbound restriction matters
The covered list is Foundayo in all formulations, Wegovy in all formulations, and Zepbound as the KwikPen only. CMS publishes the National Drug Codes for all three and notes the list was updated on 2026-04-06 to add Foundayo following its approval and to clarify the KwikPen restriction.
The excluded Zepbound presentations are the single-dose vials and the single-dose pens — and the vials are the cheapest way to buy Zepbound with cash, as our Zepbound cost page sets out. So the Bridge covers the more expensive device and not the cheaper one, which is coherent if you are running a single nationwide claims process on multi-dose pens, and is worth knowing if someone is already on vials.
Every other GLP-1 is outside the programme: Mounjaro, Ozempic in both pen and tablet form, Rybelsus, Saxenda, Victoza, Trulicity and Byetta. Several of those are the diabetes brands, which is consistent with the indication rule. Ozempic tablets and Rybelsus are not, and no reason for their exclusion is published. The full register of what each of these products is, and which are licensed for weight, is on which drugs are GLP-1s.
A bridge to something that has not been built
The name implies a far bank, and CMS's provider FAQ is candid about the state of it. The question as CMS phrases it: "What is the impact of the BALANCE Model not launching in 2027 on the Medicare GLP-1 Bridge?" The answer: the Bridge will be extended through 2027-12-31, "providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D."
Two words in that sentence are doing a lot of work: potential, and ahead. The model the Bridge was built to reach has not started in Part D, its start has already slipped once, and its implementation is described as potential rather than scheduled. The Bridge's own end date has meanwhile moved out to the end of 2027.
For anyone choosing a course of treatment on the strength of a $50 price, that is the material uncertainty, and it is not hidden — it is simply in a provider FAQ rather than in the announcement. What happens on 1 January 2028 is not published.
Where to check, and what this page cannot tell you
CMS directs beneficiaries to Medicare.gov/glp1bridge, which carries an eligibility questionnaire, or to 1-800-MEDICARE (TTY 1-877-486-2048). Prescribers have a call centre on 855-273-0102; pharmacies have a help desk on 844-673-0910. CMS also publishes a technical mailbox for the demonstration, listed on its own Medicare GLP-1 Bridge page under "Stay Connected"; it asks that enquiries to it exclude personally identifiable and protected health information.
What this page cannot tell you is whether $50 is your best price, because that depends on your own plan's formulary and cost-sharing and on whether you receive the low-income subsidy. It also cannot tell you whether a GLP-1 is appropriate for you; the criteria above are a coverage test written by a payer, not a clinical assessment, and the attestation is made by a prescriber. Our methodology sets out the line this site holds between information questions and decision questions.
Sources
All read 2026-09-19.
- CMS, Medicare GLP-1 Bridge — overview and FAQs, page last modified 2026-07-13.
- CMS, Medicare GLP-1 Bridge: Information for Pharmacies — eligibility, covered NDCs, reimbursement, fill rules, BIN/PCN.
- CMS, Medicare GLP-1 Bridge: Information for Providers — clinical criteria, the BMI-at-initiation example, the BALANCE answer.
- CMS press release, Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries, 2026-05-06.
- Medicare.gov, Weight loss drugs — beneficiary-facing eligibility and covered products.